A U G U S T 2 0, 2 0 1 2

HGS sold for $3.6B

Learn more

ImQuest developing HIV patch

Learn more

Immunovaccines cancer treatment well-received

Learn more

Developing Next Gen Solutions

With a passion for innovation, Nick Hammond, Ph.D. leads a team at Ablitech, one of Balti newest biotechnology companies focused on delivery systems for gene silencing and canc fighting treatments. Using his background working with both small animal cancer models a cell research, Hammond co-founded Ablitech in 2006 as its initial CEO and now serves as Science Officer. In addition to his experience in the discovery of novel pharmaceutical age disease treatment, Hammond also has extensive training in analytical techniques, small m synthesis and development of analytical protocols. He has authored a number of scientific presentations, and patents and holds a PhD in Medicinal Chemistry from The University of Mississippi.

Delivering the Future of Biodefense

Pathsensors has taken biodefense technology to a new level by featuring the only product market that can identify 21 biological threat agents in three minutes. Its BioFlash-E is abl detect threats, such as salmonella or E. Coli, very early in the manufacturing process prev clients from issuing a recall after a product has been shipped. The environmental and food company, based in Baltimore, plans to hire a dozen new employees in the next 18 months expand their product line and clientele.

Advancing Depression Treatment

Rockville-based biotech Neuralstem has begun testing the safety of its treatment for major depressive disorder. The compound, NSI-189, stimulates new neuron growth in the brain's hippocampus region, which scientists believe is involved in depression and other condition including Alzheimer's disease, anxiety and post-traumatic stress disorder. The phase 1b s involves two dozen depressed patients and is expected to run six months.

M-CERSI Day
September 5 | University of MD, College Park The annual showcase event of the University of Maryland Center for Excellence in Regulatory Science and Innovation will feature meetings with FDA and Maryland content experts, steering committee, advisory panel, and industrial consortia members. Learn more.

2012 Mid-Atlantic Bio Conference September 26-28 | Bethesda North Marriott

Mid-Atlantic Bio is the premier regional biotech conference for senior-level executives, policymakers, academia, financiers, media and service providers. Drawing attendance from leading industry clusters and centers of excellence the conference will bring together a critical mass of key industry stakeholders and create an ideal forum to impact the business, policy and financial climates so imperative to innovation. Learn more.

MD Stem Cell Symposium October 4-5 | Annapolis

The symposium is the Maryland Stem Cell Research Funds premier event that delivers comprehensive scientific talks, poster presentations, ethics discussions and networking time, enabling cell therapy basic research and technologies from the lab, pre-clinical and commercialization. Learn more.